Core Viewpoint - Avalon GloboCare Corp. has entered into a definitive agreement with Qi Diagnostics to co-develop a VOC nanosensor-based point-of-care cannabis breathalyzer aimed at enhancing public safety and supporting real-time detection of cannabis-impaired driving [1][2][3] Company Overview - Avalon GloboCare Corp. (NASDAQ: ALBT) specializes in precision diagnostic consumer products and is advancing intellectual property in cellular therapy [4] - The company is currently marketing the KetoAir™ breathalyzer device, which is registered with the U.S. Food and Drug Administration as a Class I medical device [4] Strategic Collaboration - The collaboration involves Avalon, its subsidiary Q&A Distribution, LLC, and Qi Diagnostics to jointly design, validate, and develop a prototype for the cannabis breathalyzer device [2] - This partnership aims to combine Avalon's regulatory expertise with Qi Diagnostics' VOC nanosensor technology to create a non-invasive cannabis detection solution [3] Public Health Impact - The cannabis breathalyzer is intended to support law enforcement and workplace safety by providing a real-time detection solution for cannabis impairment [3]

FOR IMMEDIATE RELEASE WISeSat Signs a Service Agreement with Astrocast to Allow Access to Astrocast’s Operational Satellite Constellation Geneva, Switzerland – June 25, 2025 – WISeKey International Holding Ltd (“WISeKey”) (SIX: WIHN, NASDAQ: WKEY), a leading global cybersecurity, blockchain, and IoT company, today announces that its subsidiary, WISeSat.Space, a provider of secure satellite communications and space infrastructure, signed a strategic collaboration agreement with Astrocast, a Swiss-based nanos ...

EDA：断供背景下国产替代曙光已现 2025-06-11 EDA：断供背景下国产替代曙光已现 原创 来觅研究院 RimeData 来觅数据 撰稿 李沛瑶 2025-06-11 导读：2025 年 5 月，外媒突传美国对中国 EDA 工具开始了新一轮的出口管制，意在限制我国先进制程 的突破。EDA 工具已成为国家战略安全和科技自主进步的重要抓手，它是半导体产业链最上游、壁垒最 高的环节之一，承载着从芯片功能设计到物理实现的全流程。目前国内 EDA 工具现状如何？国产替代的 难度在哪？相关投融趋势有何变化？本文尝试分析和探讨。 EDA 断供始末 EDA（Electronic Design Automation ，电子设计自动化）是一种利用计算机辅助设计（CAD）软件来 完成超大规模集成电路芯片的设计、仿真和测试等一系列设计工作的软件工具。EDA 工具在芯片设计中 有不可替代的核心作用，涵盖前端设计、后端设计、制造衔接的全流程，是复杂芯片设计的唯一途径。 美国对 EDA 工具的出口管制始于对中国半导体产业的战略遏制。2019 年，美国将华为列入实体清单， 并启动对华为的 EDA 断供。2022 年 8 月，美国商务 ...

Core Insights - The semiconductor industry is experiencing growth driven by the artificial intelligence (AI) boom, leading to a comparison between Applied Materials (AMAT) and Onto Innovation (ONTO) as potential investment picks [2] Group 1: Company Overview - Applied Materials (AMAT) is a major manufacturer of semiconductor fabrication equipment, providing solutions for deposition, etching, inspection, and metrology [3] - Onto Innovation (ONTO) specializes in metrology and inspection solutions, including automated metrology systems and advanced packaging services [10] Group 2: Financial Performance - AMAT's revenues from advanced semiconductor nodes exceeded $2.5 billion in fiscal 2024, with expectations to double in fiscal 2025 [7] - The Zacks Consensus Estimate for AMAT's fiscal 2025 revenues is $28.8 billion, reflecting a year-over-year growth of 6% [7] - ONTO's fiscal 2025 revenues are estimated at $992.6 million, indicating a modest year-over-year growth of 0.53% [13] Group 3: Growth Prospects - AMAT's integration of AI-based image recognition in its inspection solutions is expected to enhance the analysis of nanoscale defects in advanced chips [5] - ONTO's 3Di bump metrology solution is gaining traction due to the demand for complex AI chip packages, although it faces competition in the 2.5D AI packaging market [12] Group 4: Market Challenges - AMAT is positioned for continued growth in fiscal 2025, while ONTO is experiencing tool slot losses in AI packaging and revenue challenges due to US-China tensions [11] - ONTO's reliance on the Chinese market, which contributed 10% of its total revenues in fiscal 2024, raises concerns amid ongoing geopolitical tensions [13] Group 5: Valuation and Stock Performance - In the past three months, AMAT shares gained 5.8%, while ONTO shares declined by 29.4% [15] - Both companies are trading below the sector average in terms of forward price-to-sales multiples, with AMAT at 4.36X and ONTO at 4.57X, indicating AMAT is relatively cheaper [17] Group 6: Investment Outlook - AMAT is viewed as having a stronger growth profile and solid fundamentals, making it a more attractive investment compared to ONTO, which has weaker growth projections [18] - AMAT holds a Zacks Rank 3 (Hold), while ONTO has a Zacks Rank 5 (Strong Sell), indicating a clear advantage for AMAT in the current market [19]

JERUSALEM, May 30th, 2025 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) ("Scinai", or the "Company"), a biopharmaceutical company focused on developing novel and innovative biological drug candidates for the treatment of inflammation and immunology (I&I) related diseases and on providing CDMO services through its Scinai Bioservices business unit, today announced its financial results for the first three months ended March 31, 2025.Three (3) Months of 2025 Financial Summary Revenues for the t ...

Pulse Biosciences (PLSE) Q1 2025 Earnings Call May 08, 2025 04:30 PM ET Speaker0 Good afternoon, ladies and gentlemen, and welcome to the Pulse Biosciences First Quarter twenty twenty five Financial Results Conference Call. At this time, all lines are in listen only mode. Following the presentation, we will conduct a question and answer session. If at any time during this call you require immediate assistance, please press 0 for the operator. This call is being recorded on Thursday, 05/08/2025. I would like ...

Veeco Instruments Q1 2025 Financial Results Conference Call Safe Harbor May 7th, 2025 This presentation contains "forward-looking statements", within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, as amended, that are based on management's expectations, estimates, projections and assumptions. Words such as "expects," "anticipates," "plans," "believes," "scheduled," "estimates" and variations of these words and similar expressions are intended to ident ...

Core Viewpoint - Hawkins, Inc. has acquired the assets of WaterSurplus, enhancing its water treatment solutions and expanding its portfolio of value-added products, which aligns with its strategy to grow its higher-margin business [1][2][3] Financial Highlights - Hawkins generated $919 million in revenue for fiscal 2024 and anticipates its Water Treatment business to exceed $500 million in revenue in fiscal year 2026 [3][7] - WaterSurplus generated adjusted EBITDA of approximately $10 million for the fiscal year ending December 31, 2024 [6] - Hawkins closed on an amended $400 million revolving credit facility, increasing from $250 million, to fund the acquisition [6] Business Highlights - The acquisition of WaterSurplus is expected to be accretive to Hawkins' earnings per share in fiscal year 2027 and will improve the margin profile of Hawkins' current Water Treatment business [6] - Hawkins has completed 13 acquisitions over the last 5 years to build its Water Treatment business, indicating a strong integration capability [3] - WaterSurplus offers patented filtration products that reduce operational costs and enhance efficiency, which will complement Hawkins' existing offerings [9]

Pulse Biosciences, Inc. (NASDAQ:PLSE) Q4 2024 Earnings Conference Call March 27, 2025 4:30 PM ET Company Participants Philip Trip Taylor - Investor Relations Paul LaViolette - Chief Executive Officer and Co-Chairman of the Board of Directors Jon Skinner - Chief Financial Officer Conference Call Participants Operator Thank you for standing by. My name is Louella, and I will be your conference operator today. At this time, I would like to welcome everyone to the Pulse Biosciences’ Fourth Quarter 2024 Earnings ...

Canaan (CAN) Q4 2024 Earnings Call March 26, 2025 08:00 AM ET Company Participants Gwyn Lauber - Investor RelationsNangeng Zhang - Chairman & CEOJames Cheng - Chief Financial OfficerBill Papanastasiou - Vice PresidentLiang Wang - VP - Capital Markets & Corporate Development Conference Call Participants Nick Giles - Senior Research AnalystKevin Cassidy - Senior Research AnalystKevin Dede - Managing Director & Technology AnalystJoe Flynn - Senior Research Analyst Operator Ladies and gentlemen, thank you for s ...